Hemispherx Biopharma, Inc.
HEB (the "Company" or "Hemispherx") announced today the peer-reviewed
publication titled "Discordant Biological and Toxicological Species Responses
to TLR-3 Activation" in the current issue of the American Journal of Pathology
Vol. 184 (pages 1062-1072), 2014.
Toll-like receptors (TLR) are multiple proteins of the innate immune system
that trigger upon activation cascades (release) of disease fighting molecules,
which include enhancement of the body's immunity and interruption of the
replication cycles of many different viruses. Ampligen®, an experimental
therapeutic, initiates its pharmacological effects by binding TLR-3
selectively. The selectivity/ specificity of Ampligen® was first fully
described by the late Nobel Laureate in Medicine, Professor Ralph Steinman of
the Rockefeller University. The biological significance of the extraordinary
specificity of Professor Steinman's findings is illustrated in the current
manuscript.
For example, all other TLR stimulators thus far studied clinically (e.g., CpG,
Flagellins, etc.) trigger more pro-inflammatory cascades, which may lead to a
significant side effect profile in patients.
In contrast, Ampligen®, an experimental therapeutic, displayed a discordance
between the rodent and human inflammatory responses. Systemic inflammatory
cytokines, observed in rats, were correlated with significant acute and
chronic in vivo toxicities at Ampligen® doses that elicited no detectable
systemic inflammatory cytokines and minimal toxicities in primates. The lack
of systemic cytokine detection is consistent with the observed minimal
toxicity in primates, in contrast to the significant toxicities observed in
non-primates. Rat toxicity correlates with systemic cytokine levels, and the
lack of primate toxicity similarly is correlated with the lack of significant
systemic inflammatory cytokine levels.
Inflammatory cytokines observed in the systemic circulation in rats are
associated with toxicity and are analogous to the toxicity seen in humans with
lethal viral infections, such as highly pathogenic avian influenza and severe
acute respiratory syndrome-CoV associated with inflammatory cytokine storms.
Cytokine responses from baseline in seventy-six (76) patients with CFS
enrolled in two clinical trials of Ampligen® were also examined at 32 weeks
post-treatment with only one patient exhibiting a relatively high systemic
TNF-α (Tumor Necrosis Factor Alpha) level. TNF-α is a cytokine with high
inflammatory activity.
In summary, primates including humans display a relatively down-regulated
inflammatory cytokine induction pathway with TLR-3 receptor stimulation
secondary to Ampligen® administration. This down regulatory effect may
contribute to the favorable safety profile observed clinically with Ampligen®,
an experimental therapeutic.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in